Professor Michael Berk is an NHMRC Senior Principal Research Fellow and Alfred Deakin Chair of Psychiatry at Deakin University and Barwon Health, where he heads the IMPACT Strategic Research Centre. He holds an Honorary position at both Melbourne and Monash University and is a highly cited researcher with over 800 published papers predominantly in mood disorders. His major interests are in the discovery and implementation of novel therapies, and risk factors and prevention of psychiatric disorders.

Take-Home Points

• There is clinical evidence of a reduced risk of depression in people on statin therapy.

• Statins + escitalopram combined therapy has a higher response than either alone.

• Meta-analysis data show an overall effect of anti-inflammatory drugs in the treatment of depression.

Full article: [ Ссылка ]

свернуть